NonePHILADELPHIA — Joel Embiid has missed 16 games this season because of left knee injury management, knee swelling, personal reasons and a three-game suspension. But after he misses his 17th contest against the Orlando Magic, the 2023 NBA MVP will start to wade into dangerous territory and be in jeopardy, once again, of being disqualified for regular-season awards. The NBA, in cooperation with the National Basketball Players Association, instituted a 65-game rule last season for awards, hoping it would deter players and teams from leaning on load management to take off games. The seven-time All-Star was disqualified last season after playing in only 39 games. The most games Embiid can play in this season is 65 if he participates in all of the remaining contests starting with Sunday’s game against the Bulls in Chicago. But that is highly unlikely since Embiid is not expected to play on back-to-back nights because of load management. Embiid, who has missed the last six games, is averaging career lows of 19.8 points, 7.5 rebounds and 1.0 block. He’s also registering career lows of 37.9% shooting from the field and 16.7% on 3-pointers. While he’ll remain sidelined, Paul George will return after a one game of load management to face the Magic (16-8) at the Wells Fargo Center. Meanwhile, center Andre Drummond (sprained right ankle) was upgraded to questionable after being scheduled to miss the game. His status change could be tied with reserve center Adem Bona being sidelined with a bruised left knee. The Sixers (5-15) will look to avenge Wednesday’s 106-102 loss to Orlando. ©2024 The Philadelphia Inquirer. Visit inquirer.com . Distributed by Tribune Content Agency, LLC.COLUMBUS, Ohio (AP) — Will Howard passed for two touchdowns and rushed for another, TreVeyon Henderson ran for a score and No. 2 Ohio State beat previously undefeated No. 5 Indiana 38-15 on Saturday. All Ohio State (10-1, 7-1 Big Ten, CFP No. 2) has to do now is beat Michigan at home next Saturday and it will earn a return to the Big Ten championship game for the first time since 2020 and get a rematch with No. 1 Oregon. The Ducks beat Ohio State 32-31 in a wild one back on Oct. 12. The Hoosiers (10-1, 7-1, No. 5 CFP) had their best chance to beat the Buckeyes for the first time since 1988 but were hurt by special teams mistakes and disrupted by an Ohio State defense that sacked quarterback Kurtis Rourke five times. “In life, all good things come to an end,” Indiana coach Curt Cignetti said. Late in the first half, Indiana punter James Evans fumbled a snap and was buried at his own 7-yardline with the Buckeyes taking over. That turned quickly into a 4-yard TD run by Henderson that gave the Buckeyes a 14-7 lead. Early in the second half, Caleb Downs fielded an Evans punt at the Ohio State 21, raced down the right sideline, cut to the middle and outran the coverage for a TD that put the Buckeyes up 21-7. It was the first time a Buckeye returned a punt for a touchdown since 2014. Howard finished 22 for 26 for 201 yards. Emeka Egbuka had seven catches for 80 yards and a TD. “Our guys just played with a chip today, and that’s the way you got to play the game of football,” Ohio State coach Ryan Day said. Indiana scored on its first possession of the game and its last, both short runs by Ty Son Lawson, who paced the Hoosiers with 79 rushing yards. Rourke was 8 for 18 for 68 yards. “We had communication errors, pass (protection), every time we dropped back to pass, something bad happened," Cignetti said. Indiana's 151 total yards was its lowest of the season. And it was the most points surrendered by the Hoosier's defense. Indiana: Its special season was blemished by the Buckeyes, who beat the Hoosiers for the 30th straight time. Indiana was eyeing its first conference crown since sharing one with two other teams in 1967. That won't happen now. “Ohio State deserved to win,” Cignetti said. “They had those (third quarter scores), and we just couldn’t respond.” Ohio State: Didn't waste the opportunities presented by the Hoosiers when they got sloppy. The Buckeyes led 14-7 at the break and took control in the second half. An offensive line patched together because of multiple injuries performed surprisingly well. “We know what was at stake," Day said. “We don't win this game, and we have no chance to go to Indianapolis and play in the Big Ten championship. And that's real. We've had that approach for the last few weeks now, more than that.” Some voters were obviously unsure of Indiana because it hadn't played a nationally ranked team before Ohio State. After this one, the Hoosiers will drop. Howard made history by completing 80% of his passes for the sixth time this season. No other Ohio State quarterback has done that. He completed his first 14 passes in a row and finished with a 85% completion rate. “I think Buckeye nation is now seeing, after 11 games, that this guy is a winner, he's tough, he cares about his teammates, he's a leader,” Day said. Indiana hosts Purdue in the regular-season finale next Saturday. Ohio State hosts rival Michigan on Saturday. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

FOXBOROUGH, Mass. (AP) — Drake Maye’s arrival in New England coincided with a wholesale reset for the Patriots franchise following the departure of coach Bill Belichick and quarterback Mac Jones this past offseason. In his eight starts since assuming the reins from veteran Jacoby Brissett, the rookie quarterback has provided encouraging examples of what the Patriots’ revamped front office saw in selecting him third overall in the draft last April. While the Patriots enter their bye week with a 3-10 record and just 2-6 with Maye as the starter, both the coaching staff and his teammates feel they have a quarterback they can build around going forward. “I’m just trying to take it one day at a time, one game at a time,” Maye said this week. “I’m trying to learn from negative experiences or negative plays, learn from turnovers, learn from sacks that I take and see if I can get the ball out and do something better. That’s probably the biggest thing. "Hopefully, the work that we’re putting in and the product that we’re putting out can lead to some positive plays and some positive wins down the road.” Maye is coming off his best statistical performance of the season, completing a season best 80% of his passes (24 of 30) for a season-high 238 yards and a touchdown in New England’s 25-24 loss to Indianapolis. He also had a 41-yard run, showing off a running ability that has him averaging 9.1 yards per carry – best among quarterbacks who have played at least nine games. Maye did have one interception off a tipped ball, but showed his best command of offensive coordinator Alex Van Pelt’s scheme to date, spreading the ball around to six different players and consistently getting the Patriots into the red zone. The rub is that the Patriots were just 2 of 6 once they got there, including four trips inside the 10-yard line that yielded only one TD. Lackluster play in the red zone has been a hindrance for a unit that ranks 30th in the NFL in scoring touchdowns inside the 20. Maye said it will be one of his main focal points over the final four games. “It’s tough to go out like that,” Maye said. “You can’t win games going four drives in the red zone that end in field goals. We’ve got to focus in on that. I think that’s been an emphasis of improvement for this offense. We know you have to score touchdowns to win in this league.” Though coach Jerod Mayo agrees there is room for improvement for Maye, he also pointed out that the pieces around him need to do a better job supporting him as well. He pointed specifically to the offensive line, singling out rookie left guard Layden Robinson and rookie tackle Caedan Wallace, as well as fellow lineman and 2022 first-round pick Cole Strange, who is working his way back from a knee injury. “You need a guy like Layden Robinson to show what he can do. We need a guy like Cole Strange before the end of the season to see what he can do,” Mayo said. “You can use Caedan in that same bucket. We need to see what the receivers can do and what they’re going to look like going forward, and that’s the hard part for me. You want to win right now, but at the same time, I think it would be a disservice to go to the end of the season and not know exactly what we have.” That’s not lost on Robinson, who wants to play better for his quarterback who he said has grown exponentially as a leader since earning the starting job. “He always has that confidence about him and you know how he takes control of the huddle,” Robinson said. “He gets in there, and he’s like, ‘All right, let’s go to work,’ basically. We rally behind him.” Results aside, Van Pelt said there are no regrets about initially waiting to elevate Maye to the starting job. “Absolutely not. I think we had the plan going into place, and I think that it’s showing now that that was a good decision for us,” Van Pelt said. “Would he be as developed had he started the first game? Maybe. Could’ve gone the other way as well. I stated in the spring, this is a marathon, it’s not a sprint. "This is about a career, franchise quarterback, and we’re trying to develop him in the right way. And I feel like we did it that way.” AP NFL: https://apnews.com/hub/nfl

Pitt quarterback Eli Holstein leaves game with left leg injury against LouisvilleUnited Airlines travelers with lost luggage have a new tool to track their bags. If the lost bag has an Apple AirTag in it, that information can now be passed directly to United, the airline announced Thursday. The new feature, called Share Item Location, allows travelers with an AirTag or other Find My network accessory to share the location with the airline’s customer service team to help locate their luggage in the event it’s misplaced. United says more than 99% of its customers pick up their luggage without a hitch. The feature is now available with iOS 18.2, iPadOS 18.2 or macOS 15.2. “Apple’s new Share Item Location feature will help customers travel with even more confidence, knowing they have another way to access their bag’s precise location with AirTag or their Find My accessory of choice,” said David Kinzelman, United’s chief customer officer. Travelers on United whose bags do not arrive at their destination can file a delayed baggage report with United and share the link to the item’s location either through the United app or via text message. After the report has been submitted, customer service agents will be able to locate the item on an interactive map alongside a timestamp of a recent update. The shared location will be disabled after a customer has the bag, and customers can also stop sharing the location of the item at any time on their own. The location link will also automatically expire after seven days. Using AirTags or other tracking devices on luggage is increasingly popular among frequent travelers, with a significant boom following the 2022 Southwest Airlines holiday meltdown , which displaced thousands of travelers over Christmas and into 2023, alongside much of their belongings. United says lost bags are rare, with more than 99% of its customers arriving with their bags. It says the new technology will help those with lost bags to recover them more quickly because the airline will have more information about them. Apple previously announced the new service will also be integrated at other air carriers, including Delta Air Lines. Others include Aer Lingus, Air Canada, Air New Zealand, Austrian Airlines, British Airways, Brussels Airlines, Eurowings, Iberia, KLM Royal Dutch Airlines, Lufthansa, Qantas, Singapore Airlines, Swiss International Airlines, Turkish Airlines, Virgin Atlantic and Vueling. Receive the latest in local entertainment news in your inbox weekly!

Nobody doubts the level of ambition Keir Starmer is showing on housing. But will it work? That's unclear. The prime minister acknowledges that 1.5m homes in this parliament is the hardest of his milestones to meet. Today's plan tries to inject pressure on one corner of the system - the role of planning involving local councils. There are new building obligations spelt out on a council by council basis. But it is not entirely clear what happens if it's not met or the council is not co-operative. You cannot really write local plans in Whitehall. Politics latest: Starmer and Farage defend sandwiches Then there are other unsolved questions. Unlike the last building revolution in the 1960s and 70s, this revolution will be undertaken by the private sector. So land value and interest rates and other things out of the control of government play a role. More on Housing Government demands 'immediate, mandatory' housing plans from councils to build 1.5m homes Angela Rayner says newts can't be more protected than people who need housing Starmer's infrastructure promise could take until the 2040s to deliver - will it be fast enough for voters? Related Topics: Housing Then, there are more difficult areas that slow down building - the proliferation of judicial reviews, consultations and the role of habitat and nature regulations. All these are incredibly tricky to tackle - and, despite hints from the PM today, it's not clear they are being properly examined inside government. Read more: Newts can't be more protected than people Councils to get £68m to build thousands of homes Construction industry 'roaring' after rebound in house building Yet developers and experts say they're the key - and each involve big fights, the most toxic of which could be with the Labour-friendly environment movement. There are routes through that do not come at the expense of basic rights and nature, but it will take skilled technocrats and careful political handling to achieve this. The PM putting on a hard hat alone will not help him reach this target.PHILADELPHIA and PERTH, Australia , Dec. 23, 2024 /PRNewswire/ -- Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, "Arcadium Lithium"), a leading global lithium chemicals producer, today announced that it has obtained all requisite shareholder approvals in connection with the proposed acquisition by Rio Tinto previously announced on October 9 , 2024. "Today's vote of support by our shareholders confirms our shared belief that with Rio Tinto, we will be a stronger global leader in lithium chemicals production. Together, we enhance our capabilities to successfully develop and operate our assets while supporting the clean energy transition. We are confident that this transaction will provide future benefit to our customers, employees and the communities in which we operate, and I am excited by the path ahead," said Paul Graves , president and chief executive officer of Arcadium Lithium. The final voting results of Arcadium Lithium's special meetings will be filed with the Securities and Exchange Commission in a Form 8-K and will also be available at https://ir.arcadiumlithium.com . Regulatory Update As of this release, merger control clearance has been satisfied or waived in Australia , Canada , China , the United Kingdom and the United States (Hart-Scott-Rodino Antitrust Improvements Act of 1976). Additionally, investment screening approval has been satisfied in the United Kingdom . The proposed transaction is still expected to close in mid-2025, subject to the receipt of remaining regulatory approvals and other closing conditions. Arcadium Lithium Contacts Investors: Daniel Rosen +1 215 299 6208 daniel.rosen@arcadiumlithium.com Phoebe Lee +61 413 557 780 phoebe.lee@arcadiumlithium.com Media: Karen Vizental +54 9 114 414 4702 karen.vizental@arcadiumlithium.com About Arcadium Lithium Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life. Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina , Australia , Canada , China , Japan , the United Kingdom and the United States . For more information, please visit us at www.ArcadiumLithium.com . Important Information and Legal Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the completion of the transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the transaction; potential litigation relating to the transaction that could be instituted by or against Arcadium Lithium or its affiliates, directors or officers, including the effects of any outcomes related thereto; the risk that disruptions from the transaction will harm Arcadium Lithium's business, including current plans and operations; the ability of Arcadium Lithium to retain and hire key personnel; potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the transaction; certain restrictions during the pendency of the transaction that may impact Arcadium Lithium's ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the transaction; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction, including in circumstances requiring Arcadium Lithium to pay a termination fee or other expenses; competitive responses to the transaction; the supply and demand in the market for our products as well as pricing for lithium and high-performance lithium compounds; our ability to realize the anticipated benefits of the integration of the businesses of Livent and Allkem or of any future acquisitions; our ability to acquire or develop additional reserves that are economically viable; the existence, availability and profitability of mineral resources and mineral and ore reserves; the success of our production expansion efforts, research and development efforts and the development of our facilities; our ability to retain existing customers; the competition that we face in our business; the development and adoption of new battery technologies; additional funding or capital that may be required for our operations and expansion plans; political, financial and operational risks that our lithium extraction and production operations, particularly in Argentina , expose us to; physical and other risks that our operations and suppliers are subject to; our ability to satisfy customer qualification processes or customer or government quality standards; global economic conditions, including inflation, fluctuations in the price of energy and certain raw materials; the ability of our joint ventures, affiliated entities and contract manufacturers to operate according to their business plans and to fulfill their obligations; severe weather events and the effects of climate change; extensive and dynamic environmental and other laws and regulations; our ability to obtain and comply with required licenses, permits and other approvals; and other factors described under the caption entitled "Risk Factors" in Arcadium Lithium's 2023 Form 10-K filed with the SEC on February 29, 2024 , as well as Arcadium Lithium's other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations . View original content to download multimedia: https://www.prnewswire.com/news-releases/arcadium-lithium-announces-shareholder-approval-of-proposed-rio-tinto-transaction-and-provides-regulatory-update-302338409.html SOURCE Arcadium Lithium PLC

Kyle McCord leads Syracuse to first eight-win regular season in six years with win over UConnAPA Co. ( NASDAQ:APA – Free Report ) – Research analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for APA in a report issued on Tuesday, November 19th. Zacks Research analyst N. Choudhury now forecasts that the company will post earnings of $3.20 per share for the year, down from their prior estimate of $3.42. The consensus estimate for APA’s current full-year earnings is $3.97 per share. A number of other brokerages also recently issued reports on APA. Bernstein Bank lowered their price target on shares of APA from $30.00 to $28.00 in a report on Friday, October 18th. JPMorgan Chase & Co. lowered their target price on shares of APA from $29.00 to $25.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 13th. Royal Bank of Canada cut their price target on APA from $34.00 to $32.00 and set a “sector perform” rating for the company in a research note on Monday, November 11th. Piper Sandler lowered their price target on APA from $28.00 to $26.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th. Finally, Scotiabank cut their price objective on APA from $30.00 to $27.00 and set a “sector perform” rating for the company in a research report on Thursday, October 10th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $32.81. APA Price Performance Shares of NASDAQ APA opened at $22.77 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.24 and a quick ratio of 1.24. The stock has a market capitalization of $8.42 billion, a price-to-earnings ratio of 3.22 and a beta of 3.24. The firm’s 50 day simple moving average is $24.34 and its 200-day simple moving average is $27.42. APA has a 12 month low of $21.15 and a 12 month high of $37.82. Institutional Trading of APA Large investors have recently bought and sold shares of the business. TD Private Client Wealth LLC boosted its stake in APA by 84.1% during the third quarter. TD Private Client Wealth LLC now owns 1,182 shares of the company’s stock worth $29,000 after buying an additional 540 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in shares of APA by 83.7% during the 3rd quarter. Sunbelt Securities Inc. now owns 4,907 shares of the company’s stock worth $120,000 after acquiring an additional 2,236 shares during the period. Coldstream Capital Management Inc. boosted its position in shares of APA by 23.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 12,162 shares of the company’s stock valued at $296,000 after acquiring an additional 2,325 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of APA by 2.5% in the third quarter. Geode Capital Management LLC now owns 9,307,186 shares of the company’s stock valued at $226,928,000 after purchasing an additional 224,547 shares during the period. Finally, M&T Bank Corp increased its position in APA by 187.5% during the third quarter. M&T Bank Corp now owns 56,281 shares of the company’s stock worth $1,377,000 after purchasing an additional 36,707 shares during the last quarter. Hedge funds and other institutional investors own 83.01% of the company’s stock. APA Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Friday, November 22nd. Stockholders of record on Tuesday, October 22nd were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 4.39%. The ex-dividend date was Tuesday, October 22nd. APA’s dividend payout ratio is currently 14.12%. APA Company Profile ( Get Free Report ) APA Corporation, an independent energy company, explores for, develops, and produces natural gas, crude oil, and natural gas liquids. It has oil and gas operations in the United States, Egypt, and North Sea. The company also has exploration and appraisal activities in Suriname, as well as holds interests in projects located in Uruguay and internationally. See Also Receive News & Ratings for APA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for APA and related companies with MarketBeat.com's FREE daily email newsletter .Highland League: Reaction and reports as Buckie Thistle and Inverurie Locos draw while Clachnacuddin stun Brora RangersGovt will not allow any mob to damage country's economic growth: Barrister Danyal

Kyle McCord leads Syracuse to first eight-win regular season in six years with win over UConn

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable cartridge is designed specifically to treat smaller wounds up to 480 square centimeters, compared to the standard RECELL GO disposable cartridge, which treats an area of 1,920 square centimeters. RECELL GO mini addresses a critical need in the full-thickness skin defect market, which includes a high volume of smaller wounds. As part of the RECELL GO platform, RECELL GO mini uses the same multi-use processing device as the standard disposable cartridge but features a modified cartridge optimized for smaller skin samples that reduces resource use and minimizes waste. This design provides an entry point for clinicians who may not have previously used the RECELL GO platform for smaller wounds, enabling broader accessibility and use in trauma and burn centers. “The FDA approval of RECELL GO mini strengthens our ability to provide clinicians with fit-for-purpose solutions that meet the diverse needs of patients with full-thickness wounds,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “By introducing a treatment option specifically for smaller wounds, we are expanding the accessibility of RECELL to a wider range of patients. We believe this addition will drive greater adoption across trauma centers, where smaller wounds are common, and support our broader growth strategy.” The company expects RECELL GO mini to serve as a growth driver within the broader RECELL GO platform, further advancing AVITA Medical’s strategy to expand its impact on patient care. Rollout will begin with trauma and burn centers that currently treat smaller wounds during the first quarter of 2025. The PMA supplement follows the original PMA of RECELL Autologous Cell Harvesting Device and subsequent PMA supplements. About AVITA Medical, Inc. AVITA Medical is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On SkinTM Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GOTM, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit www.avitamedical.com . Forward-Looking Statements Th is press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “would,” “may,” “will,” “believe,” “continue,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; anticipated market share growth and revenue generation from certain products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b6b7df71-e67c-4a6e-847c-bdcca54fad27 Investor & Media Contact: Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.comPHILADELPHIA — Joel Embiid has missed 16 games this season because of left knee injury management, knee swelling, personal reasons and a three-game suspension. But after he misses his 17th contest against the Orlando Magic, the 2023 NBA MVP will start to wade into dangerous territory and be in jeopardy, once again, of being disqualified for regular-season awards. The NBA, in cooperation with the National Basketball Players Association, instituted a 65-game rule last season for awards, hoping it would deter players and teams from leaning on load management to take off games. The seven-time All-Star was disqualified last season after playing in only 39 games. The most games Embiid can play in this season is 65 if he participates in all of the remaining contests starting with Sunday’s game against the Bulls in Chicago. But that is highly unlikely since Embiid is not expected to play on back-to-back nights because of load management. Embiid, who has missed the last six games, is averaging career lows of 19.8 points, 7.5 rebounds and 1.0 block. He’s also registering career lows of 37.9% shooting from the field and 16.7% on 3-pointers. While he’ll remain sidelined, Paul George will return after a one game of load management to face the Magic (16-8) at the Wells Fargo Center. Meanwhile, center Andre Drummond (sprained right ankle) was upgraded to questionable after being scheduled to miss the game. His status change could be tied with reserve center Adem Bona being sidelined with a bruised left knee. The Sixers (5-15) will look to avenge Wednesday’s 106-102 loss to Orlando. ©2024 The Philadelphia Inquirer. Visit inquirer.com . Distributed by Tribune Content Agency, LLC.PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc.

Letter: You heard what?U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx ProductsBe Among the First to Experience MEGA Revolution - World's First 70W Intelligent Desktop Engraving Machine

Parallel struggles: Liberation of Karabakh and fall of Assad regimeAustralia has voted in favour of United Nations draft resolutions demanding "an immediate, unconditional and permanent ceasefire in Gaza", and supporting the mandate of UNRWA, the UN Relief and Works Agency for Palestinian refugees. The votes in the UN General Assembly come after the United States vetoed a similar action in the UN Security Council last month. Only four out of 14 Security Council votes on the Hamas-Israel war have passed, with the US, Russia and China often using their veto powers to defeat the resolutions. Australia was among 158 countries supporting the resolution for a Gaza ceasefire, which also called for the release by the military group Hamas of its Israeli hostages. Israel, the US, and seven other countries voted against it, and there were 13 abstentions. Some 159 countries voted in favour of demanding Israel reverse its ban on UNRWA and "enable its operations to proceed without impediment or restriction", while nine voted against it, and 13 abstained. This is a developing story and this article will be updated. Follow the latest from SBS News at www.sbs.com.au/news , or on the SBS News app available on iOS or Android .

AP Trending SummaryBrief at 7:07 a.m. ESTRecession-Proofing Your Portfolio With Gold